Saturday, November 14, 2026

WHO Europe Adopts Its First AI in Health Roadmap- Lifecycle Governance Becomes the Regional Model


Introduction⇒ WHO/Europe's first AI in health roadmap, adopted by 53 Member States, establishes a 2026–2033 framework for lifecycle governance, data quality, interoperability, cybersecurity, workforce competence and real-world AI evaluation.

On 29 October 2026, all 53 Member States of the WHO European Region unanimously adopted the Region’s first Roadmap for action on artificial intelligence in health. Covering 2026–2033, the roadmap establishes a common regional approach centred on governance, lifecycle oversight, data quality, interoperability, cybersecurity, workforce capability and real-world evaluation.

The roadmap is not pharmaceutical GMP guidance, but it is important for pharmaceutical companies because AI used in clinical development, digital health, real-world evidence, patient-support technologies and post-market activities increasingly operates inside the same health-system infrastructure that the roadmap is intended to govern.

[Read more…]

EMA Reveals Its AI Governance Model- Risk Assessment, Guardrails and Human-Supervised AI by 2030


Introduction⇒ EMA has published its operational AI governance model, including use-case-specific risk assessment, real-time guardrails, multidisciplinary oversight and a policy framework for human-supervised AI-enabled regulatory work by 2030.

The European Medicines Agency has published a detailed description of how it intends to govern artificial intelligence inside the European medicines regulatory network. Published on 11 November 2026, the new EMA resource describes use-case-specific AI risk assessment, technical guardrails, multidisciplinary oversight and a policy framework intended to support a transition toward AI-enabled regulatory work under human supervision by 2030.

For pharmaceutical companies, this is important even though the framework governs EMA’s own AI use: it shows how one of the world’s most influential medicines regulators is translating high-level AI principles into operational controls.

[Read more…]

Tuesday, November 10, 2026

When Regulators Use AI: IFPMA Calls for Source Verification, Sponsor-Data Protection and Global Convergence


Introduction⇒ A new IFPMA position paper calls for human accountability, source verification, sponsor-data protection, model traceability and international convergence when regulatory authorities use AI in medicinal-product review and inspection activities.

Artificial intelligence is increasingly being introduced not only by pharmaceutical companies, but also by regulatory authorities. A new IFPMA position paper, published on 9 November 2026, examines what responsible use should look like when AI supports regulatory review, scientific assessment, inspections, document preparation and other authority activities.

The paper’s central message is important for pharmaceutical companies: AI can improve regulatory capacity and efficiency, but human regulatory judgement, protection of sponsor data, source verification and accountability must remain central.

[Read more…]

Saturday, November 7, 2026

How often do pharmaceutical regulators actually identify artificial intelligence as a GMP compliance problem? From FDA enforcement to the global regulatory perspective.


Introduction⇒ A global review of AI-related GMP compliance evidence from FDA, MHRA, Swissmedic, EMA, PMDA and other regulators. What have inspectors actually identified?

How often do pharmaceutical regulators actually identify artificial intelligence as a GMP compliance problem? A recent analysis of 3,011 FDA Warning Letters found only one direct CGMP violation involving AI. But evidence from the UK, Switzerland, Japan, Europe and other regulatory authorities reveals a more complex picture: inspectors are already encountering AI-related failures, while regulatory expectations are developing faster than publicly reported enforcement cases.

[Read more…]

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has published a new regulatory reference for pharmaceutical AI


Introduction⇒ Japan's PMDA publishes AI principles covering pharmaceutical regulatory decisions, risk-based validation, data governance, lifecycle management and human oversight.

On 2 November 2026, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) published new principles for the responsible use of artificial intelligence in regulatory activities. The document explicitly includes generative AI and covers regulatory judgment and decision-making throughout the pharmaceutical lifecycle, including manufacturing and post-marketing activities.

[Read more…]